Drug General Information |
Drug ID |
D0Z1ZM
|
Drug Name |
Clarithromycin |
|
Synonyms |
Abbotic; Adel; Astromen; Biaxin; Bicrolid; CTY; Clacine; Clambiotic; Claribid; Claricide; Clarith; Clarithromycina; Clarithromycine; Clarithromycinum; Claritromicina; Clathromycin; Cyllid; Cyllind; Helas; Heliclar; Klacid; Klaciped; Klaricid; Klarid; Klarin; Klax; Kofron; Mabicrol; Macladin; Maclar; Mavid; Naxy;Veclam; Zeclar; Biaxin HP; Biaxin XL; Biaxin filmtab; Biaxin xl filmtab; Clarithromycin extended release; Clarithromycin suspension or tablets; Klaricid Pediatric; Klaricid XL; TE031; A-56268; ANX-015; Abbott-56268; Biaxin (TN); Clacid (TN); Claridar (TN); Claripen (TN); Clarithromycine [INN-French]; Clarithromycinum [INN-Latin]; Claritromicina [INN-Spanish]; Crixan (TN); DRG-0099; Fromilid (TN);Infex (TN); Klabax (TN); Klaricid (TN); Klaricid H.P; Lactoferrin B & Clarithromycin; Lactoferrin H & Clarithromycin; SDP-015; TE-031; Vikrol (TN); CLM & IL-12; CRL-1605 & Clarithromycin; Clarithromycin & Interleukin-12; Klaricid H.P.; O(6)-methylerythromycin; Clarithromycin (JP15/USP/INN); Clarithromycin [USAN:INN:BAN:JAN]; Hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame; (14R)-14-Hydroxyclarithromycin; 6-O-Methylerythromycin; 6-O-Methylerythromycin a |
Drug Type |
Small molecular drug |
Therapeutic Class |
Antibiotics |
Company |
Abbott Laboratories |
Structure |
|
Drug Resistance Mutations |
Target Name |
Bacterial 23SrRNA |
Target Info |
Species |
Helicobacter Pylori |
Targeted Disease |
Helicobacter pylori infection |
Drug Resistance Mutations |
Mutation info |
Missense: A2142C |
[1] |
|
Mutation info |
Missense: A2142G |
[1] |
|
Mutation info |
Missense: A2143G |
[1] |
Mutation Frequency |
3 out of 9 patients |
|
Mutation info |
Missense: A2144T |
[1] |
|
Mutation info |
Missense: C2694A |
[1] |
|
Mutation info |
Missense: T2717C |
[1] |
|
References |
REF 1 |
Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016 Nov 4;16(1):256.
|